Impact of Imatinib Treatment on Renal Function in Chronic
Myeloid Leukemia Patients

J 2022

Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients

SINGH, Avinash Kumar, Mohammad Salman HUSSAIN, Rayaz AHMED, Narendra AGRAWAL, Dinesh BHURANI et. al.

Basic information

Original name

Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients

Authors

SINGH, Avinash Kumar, Mohammad Salman HUSSAIN (356 India, belonging to the institution), Rayaz AHMED, Narendra AGRAWAL, Dinesh BHURANI, Miloslav KLUGAR (203 Czech Republic, belonging to the institution) and Manju SHARMA

Edition

Nephrology, Hoboken, Wiley, 2022, 1320-5358

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30217 Urology and nephrology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.500

RIV identification code

RIV/00216224:14110/22:00125092

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1111/nep.14014

UT WoS

000739713300001

Keywords in English

cancer; chronic kidney disease; chronic myeloid leukaemia;imatinib; meta-analysis; tyrosine kinase inhibitors

Abstract

V originále

Background Recently, multiple epidemiological studies have linked imatinib with the alteration of kidney function in chronic myeloid leukemia (CML) patients. This meta-analysis aimed to summarize the impact of Imatinib use on renal function in CML patients. Methods A systematic search was conducted on MEDLINE and Embase to identify articles assessing the impact of imatinib exposure on renal function in CML patients. The risk of bias was assessed using the Newcastle-Ottawa scale (NOS). Two authors independently performed literature screening, risk of bias, and data extraction. The risk of renal dysfunction (chronic kidney disease or acute kidney injury) among imatinib users was computed as the primary outcome of interest. The certainty of findings was assessed using the GRADE criteria. Results A total of nine articles qualified for inclusion in the systematic review, of which four articles were eligible for meta-analysis. Based on the scoring on NOS, majority of the included studies were found to be of moderate risk of bias. Majority of the studies (n = 6) reported significantly (p <0.05) decrease in estimated glomerular filtration rate (eGFR) after imatinib treatment. The risk of developing renal dysfunction (CKD or AKI) was found to be significantly higher in imatinib users as compared to other TKI (tyrosine kinase inhibitor) users with a pooled relative risk of 2.70 (95% CI: 1.49 – 4.91). Sensitivity analysis also revealed a consistently high risk of renal dysfunction with imatinib use. GRADE criteria revealed low certainty of evidence. Conclusion This meta-analysis found an increased risk of renal dysfunction in imatinib users compared to other TKI users.

Links

EF18_053/0016952, research and development project

Name: Postdoc2MUNI

LTC20031, research and development project

Name: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic

Investor: Ministry of Education, Youth and Sports of the CR, INTER-COST

Citovat

SINGH, Avinash Kumar, Mohammad Salman HUSSAIN, Rayaz AHMED, Narendra AGRAWAL, Dinesh BHURANI, Miloslav KLUGAR and Manju SHARMA. Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients. Nephrology. Hoboken: Wiley, 2022, vol. 27, No 4, p. 318-326. ISSN 1320-5358. Available from: https://dx.doi.org/10.1111/nep.14014.

@article{1809822,
   author = {Singh, Avinash Kumar and Hussain, Mohammad Salman and Ahmed, Rayaz and Agrawal, Narendra and Bhurani, Dinesh and Klugar, Miloslav and Sharma, Manju},
   article_location = {Hoboken},
   article_number = {4},
   doi = {http://dx.doi.org/10.1111/nep.14014},
   keywords = {cancer; chronic kidney disease; chronic myeloid leukaemia;imatinib; meta-analysis; tyrosine kinase inhibitors},
   language = {eng},
   issn = {1320-5358},
   journal = {Nephrology},
   title = {Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients},
   url = {https://onlinelibrary.wiley.com/doi/epdf/10.1111/nep.14014},
   volume = {27},
   year = {2022}
}

TY  - JOUR
ID  - 1809822
AU  - Singh, Avinash Kumar - Hussain, Mohammad Salman - Ahmed, Rayaz - Agrawal, Narendra - Bhurani, Dinesh - Klugar, Miloslav - Sharma, Manju
PY  - 2022
TI  - Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients
JF  - Nephrology
VL  - 27
IS  - 4
SP  - 318-326
EP  - 318-326
PB  - Wiley
SN  - 13205358
KW  - cancer
KW  - chronic kidney disease
KW  - chronic myeloid leukaemia;imatinib
KW  - meta-analysis
KW  - tyrosine kinase inhibitors
UR  - https://onlinelibrary.wiley.com/doi/epdf/10.1111/nep.14014
N2  - Background Recently, multiple epidemiological studies have linked imatinib with the alteration of kidney function in chronic myeloid leukemia (CML) patients. This meta-analysis aimed to summarize the impact of Imatinib use on renal function in CML patients. Methods A systematic search was conducted on MEDLINE and Embase to identify articles assessing the impact of imatinib exposure on renal function in CML patients. The risk of bias was assessed using the Newcastle-Ottawa scale (NOS). Two authors independently performed literature screening, risk of bias, and data extraction. The risk of renal dysfunction (chronic kidney disease or acute kidney injury) among imatinib users was computed as the primary outcome of interest. The certainty of findings was assessed using the GRADE criteria. Results A total of nine articles qualified for inclusion in the systematic review, of which four articles were eligible for meta-analysis. Based on the scoring on NOS, majority of the included studies were found to be of moderate risk of bias. Majority of the studies (n = 6) reported significantly (p <0.05) decrease in estimated glomerular filtration rate (eGFR) after imatinib treatment. The risk of developing renal dysfunction (CKD or AKI) was found to be significantly higher in imatinib users as compared to other TKI (tyrosine kinase inhibitor) users with a pooled relative risk of 2.70 (95% CI: 1.49 – 4.91). Sensitivity analysis also revealed a consistently high risk of renal dysfunction with imatinib use. GRADE criteria revealed low certainty of evidence. Conclusion This meta-analysis found an increased risk of renal dysfunction in imatinib users compared to other TKI users.
ER  -

SINGH, Avinash Kumar, Mohammad Salman HUSSAIN, Rayaz AHMED, Narendra AGRAWAL, Dinesh BHURANI, Miloslav KLUGAR and Manju SHARMA. Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients. \textit{Nephrology}. Hoboken: Wiley, 2022, vol.~27, No~4, p.~318-326. ISSN~1320-5358. Available from: https://dx.doi.org/10.1111/nep.14014.

Detailed Information on Publication Record